Latest From Nanobiotix SA
Laurent Levy tells Scrip Nanobiotix’s freshly-created subsidiary Curadigm aims to improve bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
The CE mark will make Hensify nanoparticle radioenhancers available in 27 European countries. Hensify is the brand name for NBTXR3, an aqueous suspension of crystalline hafnium oxide nanoparticles, approved specifically for treating locally advanced soft-tissue sarcoma.
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
- Nanotechnology, Chips, etc.
- Drug Delivery
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Nanobiotix SA
- Senior Management
Patrick Tricoli, PharmD, CEO & Global Head, Bus. Dev.
Philippe Mauberna, CFO
Edwina Baskin-Bey, MD, CMO
Brandon Owens, VP, Strategic Mktg. & Corp. Communications
- Contact Info
Phone: (33) 1 40 26 04 70
60 rue de Wattignies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.